A medical investigator, Robert Hindes, MD, has co-authored numerous studies documenting the safety and efficacy of sofosbuvir, a drug recently approved by the U.S. Food and Drug Administration for addressing hepatitis C virus (HCV) infections. According to recent research conducted by Robert Hindes, MD, and his colleagues, sofosbuvir has demonstrated excellent efficacy against drug-resistant hepatitis C when combined with daclatasvir. Patients involved in the study took both medications as a once-daily oral treatment. High SVR rates were achieved in treatment-naive patients and in patients who had previously failed therapy with protease inhibitors
Of the individuals participating in the study, two stopped taking the medications owing to adverse events. One patient began exhibiting symptoms of fibromyalgia, while the other experienced a serious cardiovascular event not considered drug related. Despite the shortened duration of treatment, both patients demonstrated a virologic response to the drugs, an indication that even shorter durations of therapy may be effective.
The paper was published in the January 16, 2014, issue of the New England Journal of Medicine as "Daclatasvir Plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection."
Of the individuals participating in the study, two stopped taking the medications owing to adverse events. One patient began exhibiting symptoms of fibromyalgia, while the other experienced a serious cardiovascular event not considered drug related. Despite the shortened duration of treatment, both patients demonstrated a virologic response to the drugs, an indication that even shorter durations of therapy may be effective.
The paper was published in the January 16, 2014, issue of the New England Journal of Medicine as "Daclatasvir Plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection."